Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / LXRP - Lexaria Bioscience on go with pilot study of antiviral drug delivery technology for potential use in COVID-19

LXRP - Lexaria Bioscience on go with pilot study of antiviral drug delivery technology for potential use in COVID-19

Lexaria Bioscience Corp.
Lexaria Bioscience (LXRP) has received a conditional approval from the Human Research Ethics Committee in addition to government regulatory approval to conduct a pilot study in healthy volunteers of antiviral drugs that have previously been studied against coronavirus strains other than SARS-CoV-2, comparing its DehydraTECHTM formulations to controls without the technology.The study will investigate how its DehydraTECH drug delivery technology could enhance the delivery and effectiveness of certain antivirals against COVID-19.Additionally, the company has launched an animal antiviral drug delivery study with potential COVID-19 applications. Dosing of the rodents has already begun with results expected in December.Previously: Lexaria Bio begins COVID-19 drug delivery program (Mar 19)

For further details see:

Lexaria Bioscience on go with pilot study of antiviral drug delivery technology for potential use in COVID-19
Stock Information
Company Name: Lexaria Bioscience Corp.
Stock Symbol: LXRP
Market: OTC
Website: lexariabioscience.com
Menu
LXRP LXRP Quote LXRP Short LXRP News LXRP Articles LXRP Message Board
Get LXRP Alerts

News, Short Squeeze, Breakout and More Instantly...